doi: 10.3389/fphar.2023.1142001 Received 11 January 2023 Accepted 06 March 2023 Published 15 March 2023 Volume 14 - 2023 Edited by Xiaoxin Wang, Georgetown University Medical Center, United States Reviewed by Anil Bhanudas Gaikwad, Birla Institute of Technology and Science, India Komuraiah Myakala, Georgetown University, United States Updates Copyright 2023 Huang, Liang and Zhou
While patients require a medical history of MASH, liver biopsy might not be absolutely required for medication approval and may be supplemented by liver fibrosis imaging (transient elastography [FibroScan] or magnetic resonance elastography) and noninvasive fibrosis scoring (fibrosis-4 index)
GHRP-2 was specifically designed to deliver greater GHS-R1a binding potency and enhanced GH-releasing efficacy relative to the founding GHRP-6, while retaining the hexapeptide structural scaffold
Serious but Less Common Side Effects: Pancreatitis: Although rare, there is a risk of acute pancreatitis